CAJ | 학술논문

二肽基肽酶Ⅳ抑制剂(DPP-4抑制剂)是一种新的糖尿病治疗药物，其能安全有效降糖，又能改善胰岛素抵抗，为2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的转归提供一种新的可能，是近年研究的热点。本文就其在T2DM合并NAFLD治疗中可能的疗效和临床证据进行综述。
이태기태매Ⅳ억제제(DPP-4억제제)시일충신적당뇨병치료약물，기능안전유효강당，우능개선이도소저항，위2형당뇨병(T2DM)합병비주정성지방간(NAFLD)적전귀제공일충신적가능，시근년연구적열점。본문취기재T2DM합병NAFLD치료중가능적료효화림상증거진행종술。
Dipeptidyl peptidaseⅣinhibitors (DPP-4 inhibitor) was a new oral drug for the treatment of dia-betes, which not only decresed blood glucose safely and effectively, but also improved the insulin resistance and pro-vided a new possibility for the outcome of type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver dis-ease (NAFLD). This article reviewed its efficacy and clinical evidence of T2DM with NAFLD .